Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?
Landon C BrownGuru SonpavdeAndrew J ArmstrongPublished in: Prostate cancer and prostatic diseases (2018)
Objective responses in men with mCRPC may be associated with prolonged survival, but this association is mechanism dependent and inconsistent across trials or disease states. These data support considering RECIST response as a supportive but not sole endpoint in phase 2 trials to support launching phase 3 trials.